Abstract
The effects of the dopamine agonist bromocryptine on several measures dopaminergic function were assessed in the rat. Following inhibition of impulse flow with gamma-butyrolactone, and after dopa decarboxylase inhibition, dopa accumulation and its reversal by dopamine agonists is easily studied. In this model, bromocryptine (10 mg/kg, i.p.) caused a significant decrease in dopa accumulation in both the striatum and olfactory tubercle which was prevented, but not reversed, by the dopamine antagonist (+)-butaclamol (4 mg/mg, i.p.). The inactive isomer, (-)-butaclamol was without effect. Analysis of an vitro 3H-spiperone binding 2h after bromocryptine (10 mg/kg, i.p.) revealed a 30% decrease in the number of striatal dopamine receptors labelled (Bmax), with no change in receptor affinity for 3H-spiperone. No changes in binding were seen when animals were sacrificed 30 min or 48 h after bromocryptine. In extracellular single unit recording experiments, bromocryptine-induced depression of nigrostriatal dopamine cell firing was found to be largely reversible by the dopamine antagonist haloperidol when injected within 5 min of intravenous bromocryptine. However, when haloperidol was injected more than 20 min after bromocryptine, no re...Continue Reading
References
Dec 29, 1976·Naunyn-Schmiedeberg's Archives of Pharmacology·J R Walters, R H Roth
Oct 23, 1978·Life Sciences·B S Bunney, A A Grace
Feb 1, 1979·Clinical Endocrinology·T YeoG M Besser
Mar 26, 1979·Life Sciences·H H Keller, M Da Prada
Jul 7, 1978·Brain Research·P G Guyenet, G K Aghajanian
Dec 1, 1977·Life Sciences·E E MůllerP Mantegazza
Sep 12, 1978·Naunyn-Schmiedeberg's Archives of Pharmacology·M Quik, L L Iversen
Jan 1, 1979·Dental Hygiene·C Palmer
Dec 15, 1977·European Journal of Pharmacology·I CreeseS H Snyder
Apr 10, 1965·Nature·R C Thomas, V J Wilson
Jan 1, 1972·Naunyn-Schmiedeberg's Archives of Pharmacology·W KehrM Lindqvist
Mar 20, 1966·Journal of the American Chemical Society·H OttA J Frey
Mar 21, 1980·European Journal of Pharmacology·K L Marek, R H Roth
Citations
Oct 1, 1989·Naunyn-Schmiedeberg's Archives of Pharmacology·D M JacksonL G Larsson
Jan 1, 1981·Psychopharmacology·R L WeirE K Silbergeld
Jan 1, 1983·Psychopharmacology·H Y MeltzerB J Tricou
Jan 1, 1987·Journal of Neural Transmission·D M Jackson, M Hashizume
Jan 1, 1985·Journal of Neural Transmission·D M Jackson, O F Jenkins
May 1, 1996·Psychopharmacology·B A MattinglyM T Bardo
Nov 14, 1983·Brain Research·A L GundlachP M Beart
Aug 26, 1985·Brain Research·G PizzolatoS I Rapoport
Mar 21, 1980·European Journal of Pharmacology·K L Marek, R H Roth
Jul 30, 1982·European Journal of Pharmacology·A M HoloheanJ B Appel
Nov 5, 1982·European Journal of Pharmacology·A ArgiolasG L Gessa
Apr 13, 1984·European Journal of Pharmacology·D A BergstromJ R Walters
Mar 16, 1984·European Journal of Pharmacology·G G YarbroughG E Martin
Mar 16, 1984·European Journal of Pharmacology·M J CroninM O Thorner
Sep 19, 1996·European Journal of Pharmacology·M F PierceyD K Hyslop
Oct 5, 1987·Life Sciences·G ForloniS Consolo
Jun 1, 1983·Neuropharmacology·F J White, R Y Wang
Feb 1, 1986·Pharmacology, Biochemistry, and Behavior·F J White
Aug 1, 1989·Pharmacology, Biochemistry, and Behavior·K KumorJ Jaffe
Jan 1, 1983·Neuroscience and Biobehavioral Reviews·J N Joyce
Jan 1, 1994·Pharmacology & Therapeutics·D M Jackson, A Westlind-Danielsson
Jul 11, 2002·European Journal of Pharmacology·Giorgio MarcheseLuca Pani
Jul 1, 1997·Trends in Pharmacological Sciences·N B MercuriG Bernardi
Apr 30, 1998·Progress in Neurobiology·M E Wolf
Aug 1, 1985·Journal of Pharmacological Methods·H Watanabe
Jan 1, 1984·Journal of Neurochemistry·I S Hoffmann, L X Cubeddu
Apr 7, 1987·Brain Research·G MereuG L Gessa
Dec 22, 1983·Nature·M J BannonL L Iversen
Apr 1, 1985·Medicinal Research Reviews·C Kaiser, T Jain
Oct 1, 1981·The Journal of Pharmacy and Pharmacology·P R Sanberg, I Creese
Jan 1, 1988·Neuroscience and Biobehavioral Reviews·L A Chiodo